Trypanosoma cruzi: 4-aminopyrazolopyrimidine in the treatment of experimental Chagas' disease.
An allopurinol metabolite, 4-aminopyrazolopyrimidine, was tested on two different strains of mice (NMRI-IVIC and C57Bl/6J) that had been infected 4 days earlier with the virulent Ya strain of Trypanosoma cruzi. Low doses of 4-aminopyrazolopyrimidine (0.125-0.500 mg/kg body wt/day) for 10 days induced a significant reduction in parasitemia (direct counts and subinoculation experiments) and increased survival time (without any evidence of toxicity) compared with untreated animals. When tested in vitro, 4-aminopyrazolopyrimidine was sixfold more active than allopurinol as a trypanostatic drug. The low therapeutic doses of 4-aminopyrazolopyrimidine suggest that this drug may be useful in the treatment of acute Chagas' disease.
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology; D008099:Liver / Q000187:drug effects / Q000469:parasitology; D051379:Mice; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000469:parasitology; D014349:Trypanosoma cruzi / Q000187:drug effects
D000981:Antiprotozoal Agents; C004420:4-aminopyrazolo(3,4-d)pyrimidine; D000225:Adenine